Efficacy, Safety and Tolerability of PrasugrEl 5mg or TIcagrelor 60mg in COmplex and Higher-Risk Indicated PCI/PatieNts: The Prospective, Randomized, Open-labeled, Blinded Endpoint (PROBE), Multi-center E5TION Trial
Overview
- Phase
- Phase 4
- Enrollment
- 492
- Locations
- 8
- Primary Endpoint
- Major bleeding and adherence to DAPT regimen
Overview
Brief Summary
E5TION will evaluate the efficacy, safety and tolerability of tailored two regimens (prasugrel 5mg/d vs. ticagrelor 60mg bid) in high-risk patients undergoing PCI (CHIP: COmplex and Higher-Risk Indicated PCI/PatieNts).
Detailed Description
Because CHIP (COmplex and Higher-Risk Indicated PCI/PatieNts) has been related with the increased risk of ischemic events following PCI, there are unmet needs to develop the tailored strategies (e.g., intensified antiplatelet treatment) for this cohort. During antithrombotic treatment, East Asian patients have been prone to bleed compared with Western patients ("East Asian Paradox"). For example, standard-dose potent P2Y12 inhibitors (e.g., ticagrelor, prasugrel) vs. clopidogrel did not demonstrate the better net clinical benefit in patients with acute coronary syndrome. One of the tailored antiplatelet strategies for East Asian patients would be the de-escalated strategy of potent P2Y12 inhibitors (e.g., ticagrelor, prasugrel). The ISAR-REACT5 trial showed the lower ischemic event and better tolerability of ticagrelor vs. prasugrel in ACS patients. This E5TION trial will compare the efficacy, safety and tolerability of the de-escalated strategies (low-dose prasugrel and ticagrelor) in East Asian patients with CHIP character.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 19 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age 19 and more; and
- •Subjects who scheduled for percutaneous coronary intervention(PCI) with Firehawk® drug-eluting stent
- •At least one of the following high-risk factors;
- •Clinical factors: diabetes, chronic kidney disease (GFR \< 60ml/min/1.73m2), LV dysfunction (LV EF \< 45%), or troponin (+).
- •Lesion- or procedure-related factors: left main PCI, chronic total occlusion, bifurcation lesion requiring two-stent technique, severe calcification, in-stent restenosis, multi-vessel PCI (≥ 2 vessels requiring stent implantation), PCI for ≥ 3 lesions, ≥ 3 stents implanted, or total stent length \> 60 mm.
- •High platelet reactivity: VerifyNow PRU ≥ 266.
Exclusion Criteria
- •Cardiogenic shock at the index admission
- •Bleeding tendency, congenital or acquired
- •Active bleeding or high-risk for major bleeding (e.g. active peptic ulcer disease, gastrointestinal pathology with a high-risk for bleeding, malignancies with a high-risk for bleeding)
- •Need for chronic oral anticoagulation
- •History of intracranial hemorrhage
- •Intracranial neoplasm, AV fistula or aneurysm
- •Platelet counts \< 100,000/mm3
- •Liver cirrhosis with ascites or coagulopathy
- •Dialysis-impending or -dependent renal failure
- •Pregnant and/or lactating women
Arms & Interventions
E5 group
Escalation in CHIP
Intervention: Prasugrel 5mg (Drug)
T60 group
Escalation in CHIP
Intervention: Ticagrelor 60mg (Drug)
Outcomes
Primary Outcomes
Major bleeding and adherence to DAPT regimen
Time Frame: 1 year after PCI
Incidence of major bleeding (BARC type 2, 3 or 5) and prevalence of discontinuation/switch of antiplatelet regimen
Secondary Outcomes
- MACE(1 year after PCI)
- Major bleeding(1 year post-PCI)
- Adherence to DAPT regimen(1 year after PCI)